Lung cancer treatment in the era of immunotherapy

Yang, Xu; Chen, Liangan

doi:10.1097/cm9.0000000000001116

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Now, immunotherapy is moving toward neoadjuvant and adjuvant treatments for early-stage NSCLC. [2][3][4][5][6][7][8][9] Immunotherapy strategies include single-agent immune checkpoint inhibitors (ICIs) in monotherapy and combination therapies. Several studies have shown that the population that benefits from single-agent ICI therapy is limited and may have a hyper-progressive response pattern.…”

Section: Introductionmentioning

confidence: 99%

“…PD-1/PD-L1 inhibitors were initially used as second-line treatments but were upgraded as first-line treatments for advanced lung cancer and unresectable locally advanced non-small cell lung cancer (NSCLC). Now, immunotherapy is moving toward neoadjuvant and adjuvant treatments for early-stage NSCLC [2–9] . Immunotherapy strategies include single-agent immune checkpoint inhibitors (ICIs) in monotherapy and combination therapies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer

Cheng

Zhang

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

In recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer (NSCLC). However, owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon, it may not meet clinical needs. To expand the beneficial range of immunotherapy and improve its efficacy, several research strategies have adopted the use of combination immunotherapy. At present, multiple strategies, such as PD-1/PD-L1 inhibitors combined with chemotherapy, anti-angiogenic therapy, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and radiotherapy, as well as combined treatment with new target drugs, have been evaluated for clinical practice. To further understand the current status and future development direction of immunotherapy, herein, we review the recent progress of ICI combination therapies for NSCLC.

show abstract